1. Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not useful;Parasrampuria;Basic Clin Pharmacol Toxicol,2015
2. Building global development strategies for CF therapeutics during a transitional CFTR modulator era;Mayer-Hamblett;J Cyst Fibros,2020
3. U.S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry. E 10 Choice of Control Group and Related Issues in Clinical Trials. 2001. https://www.fda.gov/media/71349/download. Accessed on October 18, 2023.
4. U.S. Department of Health and Human Services Food and Drug Administration, Rare Diseases: Common Issues in Drug Development. Guidance for Industry. 2019. https://www.fda.gov/media/119757/download. Accessed on October 18, 2023.
5. U.S. Department of Health and Human Services Food and Drug Administration, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products. 2019. https://www.fda.gov/media/133660/download. Accessed on October 18, 2023.